It has been accepted that Zoledronic acid (ZA)(Zometa) reduces the onset risk of skeletal-related events (SRE) caused by bone metastasis in prostate cancer as well as improving their quality of life (QOL). ZA has become a standard supportive therapy for men with prostate cancer who have bone metastasis. However, there is an issue which I [...]
Malecare has recently launched a newsletter specifically about advanced, metastatic prostate cancer. This is the only Newsletter in publication that is dedicated exclusively to advanced prostate cancer. Everything in the newsletter is about advanced prostate cancer and every article is actionable by you. The Newsletter is about things that you can use today to improve [...]
As I have said before, the true unsung heroes of our fight against advanced prostate cancer are our caretakers. Our caretakers are our saints, they help educate us, they advocate for us, they shield us and they make us as complete as we can possibly be. They improve our lives and help us get through [...]
Some men with advanced prostate cancer have been given the antifungal treatment Ketoconazole (Keto) as a second line hormone treatment. Like Keto, this newer hormone treatment that is now available, Abiraterone acetate (AA) (Zytiga) works by inhibiting CYP17, the rate-limiting enzyme in androgen biosynthesis. The question being asked, if Keto has failed ,given its similar [...]
Since its FDA approval in 2011 FDA abiraterone (Zytiga) has supplanted docetaxel (chemotherapy), other than perhaps Provenge, as preferred first-line treatment for metastatic castrate-resistant prostate cancer. August 2012 saw the FDA approval of enzalutamide (Xtandi) for the treatment of castrate-resistant prostate cancer after chemotherapy. Researchers performed a retrospective chart review at a large medical oncology [...]